Catalyst Dossier · compiled by CeliA 🧫

Bausch & Lomb (BLCO)

Ophthalmic Goods · market cap $5.3B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-29

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Bausch & Lomb (BLCO) is a large-cap Canadian ophthalmic goods company with ~$5.1B in annual revenue, a sprawling pipeline across contact lenses, surgical products, and ophthalmic pharmaceuticals. The company carries $4.8B in net debt against $268M cash, generating persistent net losses despite consistent revenue growth. The stock trades near $15.91 with analyst consensus buy and a mean target of ~$17.88.

The catalyst path

2026-07-29Earningsimp 5/10
2026-11-15 (est.)Phase 2 · Lifitegrast/Perfluorohexyloctane Fixed Dose Combinationimp 7/10

Pipeline

Asset	Phase	Indication
Loteprednol Etabonate Gel (BID)	Phase 3	Inflammation
Bromfenac Ophthalmic Solution	Phase 3	Pain
bromfenac ophthalmic solution 0.06%	Phase 2	Dry Eye Disease
brinzolamide 1% ophthalmic suspension	Phase 3	Glaucoma
0.5% Loteprednol Etabonate Ophthalmic Ointment	Phase 3	Ocular Inflammation
BOL-303259-X	Phase 3	Ocular Hypertension
0.59 mg fluocinolone acetonide intravitreal implant	Phase 2	Diabetic Macular Edema
Bromfenac	Phase 3	Postoperative Complications
Loteprednol etabonate	Phase 3	Cataract
Besivance	Phase 3	Bacterial Conjunctivitis
Loteprednol Etabonate Gel (TID)	Phase 3	Inflammation
EM-100	Phase 3	Allergic Conjunctivitis
Brimonidine Tartrate	Phase 3	Hyperemia
Latanoprostene bunod	Phase 3	Glaucoma
Bepotastine besilate	Phase 3	Seasonal Allergic Rhinitis
Ketotifen/naphazoline	Phase 3	Allergic Conjunctivitis
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution	Phase 3	Seasonal Allergic Conjunctivitis
ecabet ophthalmic solution	Phase 2	Dry Eye Disease
Loteprednol Etabonate Ophthalmic Gel dosed TID	Phase 3	Cataract
Bromfenac Ophthalmic Solution A	Phase 3	Dry Eye Syndrome

Price & technical context

3-month

+4.1%

6-month

-3.5%

12-month

+23.0%

52-wk range

$13.45–$18.60

vs 50-day MA

+5.1%

vs 200-day MA

+2.3%

Realized vol

30.3%

Max drawdown

-47.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BLCO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.